Literature DB >> 25048644

LRRK2-G2019S mutation is not associated with an increased cancer risk: a kin-cohort study.

Roberta Allegra1, Sara Tunesi, Roberto Cilia, Gianni Pezzoli, Stefano Goldwurm.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 25048644     DOI： 10.1002/mds.25969

Source DB:  PubMed          Journal:  Mov Disord        ISSN： 0885-3185            Impact factor:   10.338


× No keyword cloud information.
  8 in total

1.  Cancer outcomes among Parkinson's disease patients with leucine rich repeat kinase 2 mutations, idiopathic Parkinson's disease patients, and nonaffected controls.

Authors:  Ilir Agalliu; Roberto A Ortega; Marta San Luciano; Anat Mirelman; Claustre Pont-Sunyer; Kathrin Brockmann; Dolores Vilas; Eduardo Tolosa; Daniela Berg; Bjørg Warø; Amanda Glickman; Deborah Raymond; Rivka Inzelberg; Javier Ruiz-Martinez; Elisabet Mondragon; Eitan Friedman; Sharon Hassin-Baer; Roy N Alcalay; Helen Mejia-Santana; Jan Aasly; Tatiana Foroud; Karen Marder; Nir Giladi; Susan Bressman; Rachel Saunders-Pullman
Journal:  Mov Disord       Date:  2019-07-26       Impact factor: 10.338

2.  Exploring cancer in LRRK2 mutation carriers and idiopathic Parkinson's disease.

Authors:  Bjørg Johanne Warø; Jan O Aasly
Journal:  Brain Behav       Date:  2017-12-07       Impact factor: 2.708

3.  Comprehensive Genomic Analysis Reveals the Prognostic Role of LRRK2 Copy-Number Variations in Human Malignancies.

Authors:  Gianluca Lopez; Giulia Lazzeri; Alessandra Rappa; Giuseppe Isimbaldi; Fulvia Milena Cribiù; Elena Guerini-Rocco; Stefano Ferrero; Valentina Vaira; Alessio Di Fonzo
Journal:  Genes (Basel)       Date:  2020-07-24       Impact factor: 4.096

4.  Parkinson's disease and cancer: a systematic review and meta-analysis on the influence of lifestyle habits, genetic variants, and gender.

Authors:  Joon Yan Selene Lee; Jing Han Ng; Seyed Ehsan Saffari; Eng-King Tan
Journal:  Aging (Albany NY)       Date:  2022-03-05       Impact factor: 5.682

5.  Leucine-Rich Repeat Kinase 2 (LRRK2) phosphorylates p53 and induces p21(WAF1/CIP1) expression.

Authors:  Dong Hwan Ho; Hyejung Kim; Jisun Kim; Hyuna Sim; Hyunjun Ahn; Janghwan Kim; Hyemyung Seo; Kwang Chul Chung; Bum-Joon Park; Ilhong Son; Wongi Seol
Journal:  Mol Brain       Date:  2015-09-18       Impact factor: 4.041

Review 6.  The associations between Parkinson's disease and cancer: the plot thickens.

Authors:  Danielle D Feng; Waijiao Cai; Xiqun Chen
Journal:  Transl Neurodegener       Date:  2015-10-26       Impact factor: 8.014

Review 7.  LRRK2 Biology from structure to dysfunction: research progresses, but the themes remain the same.

Authors:  Daniel C Berwick; George R Heaton; Sonia Azeggagh; Kirsten Harvey
Journal:  Mol Neurodegener       Date:  2019-12-21       Impact factor: 14.195

8.  TM4SF4 and LRRK2 Are Potential Therapeutic Targets in Lung and Breast Cancers through Outlier Analysis.

Authors:  Kyungsoo Jung; Joon-Seok Choi; Beom-Mo Koo; Yu Jin Kim; Ji-Young Song; Minjung Sung; Eun Sol Chang; Ka-Won Noh; Sungbin An; Mi-Sook Lee; Kyoung Song; Hannah Lee; Ryong Nam Kim; Young Kee Shin; Doo-Yi Oh; Yoon-La Choi
Journal:  Cancer Res Treat       Date:  2020-09-16       Impact factor: 4.679
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.